Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma

IMPORTANCE: Atezolizumab plus bevacizumab as a first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma has been shown to improve overall and progression-free survival compared with standard sorafenib treatment. However, because of the high cost of atezolizumab plus b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin, Wang, Jingjing, Shi, Juanjuan, Jia, Xiaoli, Dang, Shuangsuo, Wang, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027915/
https://www.ncbi.nlm.nih.gov/pubmed/33825837
http://dx.doi.org/10.1001/jamanetworkopen.2021.4846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027915/
https://www.ncbi.nlm.nih.gov/pubmed/33825837
http://dx.doi.org/10.1001/jamanetworkopen.2021.4846

Ejemplares similares